Levosert One

Levonorgestrel, the active ingredient in Levosert One, is a progestin presented as an intrauterine system for intrauterine use. The device continuously releases levonorgestrel directly into the uterine cavity, delivering effective, long‑acting reversible contraception and preventing pregnancy in women of reproductive age.

GNH USA supplies Levosert One as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance for global distribution. The company adheres to stringent Good Distribution Practice standards and provides comprehensive documentation to meet the requirements of health authorities across the European Union and other markets.

Levonorgestrel, a progestin hormone, is used as a long‑acting reversible contraceptive delivered via an intrauterine system. - Contraception: provides continuous, hormone‑based birth control for up to five years, reducing the need for daily pills. - Pregnancy prevention: maintains effective prevention of pregnancy throughout the device’s lifespan when correctly placed. - Management of heavy menstrual bleeding: can reduce menstrual blood loss and improve cycle regularity in women with dysfunctional uterine bleeding.

Levosert One may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular vaginal bleeding or spotting - Prolonged periods or amenorrhea - Breast tenderness - Abdominal discomfort

Serious or Rare Side Effects: - Uterine perforation during insertion - Pelvic inflammatory infection - Ectopic pregnancy

Before insertion of Levosert One, clinicians should observe several precautionary measures to ensure safety and effectiveness. - Confirm non‑pregnant status: verify absence of pregnancy before device placement. - Screen for active pelvic infection: defer insertion until infection resolved. - Evaluate uterine anatomy: ensure cavity size and shape are suitable for IUS placement. - Counsel on bleeding changes: inform patient about possible irregular bleeding patterns. - Store at room temperature: keep the device in its original packaging, protect from moisture and direct sunlight.

Levosert One’s hormonal release can be affected by certain concomitant medicines, requiring attention to potential interactions.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may markedly reduce levonorgestrel efficacy. - Rifampin or other strong CYP3A4 inducers: can lower hormone levels and increase risk of contraceptive failure.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly diminish contraceptive effect. - Antiretroviral agents (e.g., efavirenz): may reduce levonorgestrel concentrations. - Herbal supplements such as St. John’s wort: potential to increase hormone metabolism.